Retatrutide, is being studied as a triple hormone receptor agonist. It is designed to activate three metabolic hormone pathways: GIP, GLP-1, and glucagon receptors. Because of this triple-action profile, retatrutide is being investigated in research related to body-weight regulation, appetite signaling, glucose metabolism, energy expenditure, liver-fat reduction, and broader cardiometabolic health markers.
Potential Research Benefits
- Body-weight regulation research
- Appetite and satiety signaling
- Food-intake and craving-related pathways
- GLP-1 receptor pathway research
- GIP receptor pathway research
- Glucagon receptor pathway research
- Energy-expenditure and metabolic-rate research
- Fat-mass reduction research
For laboratory and research use only. Not for human consumption.
This product is a research chemical. It is not a drug, food or cosmetic, and it is not for human or veterinary use. It is sold exclusively to qualified researchers and licensed laboratories.
This product has not been evaluated or approved by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.
